HAE Haemoneticsdata gap · 92% coverage
Health Care · Health Care Supplies · close $118.28 (2026-10-16) · latest quarter in EDGAR: 2026-06-27
Haemonetics (HAE) has a ThetaGrade House Rating of 43/100 (grade D), ranking #135 of 150 in Health Care. Its strongest pillars are cash flow (74) and profitability (65); its weakest is growth (23). Data gap: 2 factors without usable data, so 92% of the method weight is covered. TTM revenue growth is 0.4% and operating margin 11.9%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 92% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 23| Revenue growth YoY (TTM) (13.3%) | 0.4% | 9 |
| EPS growth YoY (TTM) (13.3%) | -36.7% | 19 |
| Revenue acceleration (6.7%) | 0.8% | 61 |
Profitability
weight 18.5% (→20.0%) · 65| Operating margin (10.7%) | 11.9% | 47 |
| 4Q gross-margin change (9.3%) | 2.1% | 85 |
Balance sheet
weight 18.5% (→20.0%) · 38| Net debt / EBITDA (10.7%) | 3.50× | 18 |
| Current ratio (5.3%) | 3.08 | 59 |
| Interest coverage (4.0%) | 8.31× | 65 |
Cash flow
weight 12.33% (→13.3%) · 74| FCF margin (6.7%) | 19.5% | 71 |
| FCF yield (6.7%) | 4.8% | 76 |
Valuation
weight 12.33% (→13.3%) · 37| P/E (inverted) (6.7%) | 57.14× | 19 |
| EV/Sales (inverted) (6.7%) | 4.68× | 55 |
Technicals (EOD)
| RSI(14) | 66.3 |
| EMA 9 / 21 | 116.94 / 112.14 |
| 200-day SMA | 76.77 |
| Volume vs 20d avg | 0.64× |
| 20-day return | 9.9% |
Exit-rule monitor
- EXITRating break: House Rating below 60
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: GrossProfit · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseDebt · D&A: DepreciationAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like HAE's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is HAE's House Rating?
- HAE scores 43 out of 100 (grade D) as of 2026-10-16, ranking #135 of 150 Health Care stocks we cover.
- What do analysts say about HAE?
- We do not have enough analyst-sentiment data to score this stock.
- When does HAE report earnings next?
- HAE's next earnings report is estimated for about 2026-11-05 (window 2026-11-02 to 2026-11-08), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is HAE a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology